Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
Date:1/8/2014

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets.  The collaboration is intended to accelerate the time from discovery to development with the potential to deliver first-in-class treatments that address significant unmet medical needs.  Funding is channeled into the most promising targets to drive early research before moving into larger scale clinical development. 

"This collaboration strengthens our ability to access potential breakthrough innovation, and demonstrates our continued commitment to working with partners at the forefront of science," said Mahmoud Ghazzi, M.D., Ph.D., Global Head of Development, Daiichi Sankyo, Co. Ltd.  "By augmenting in-house research and other development avenues, these focused, exclusive, indication-targeted partnerships can accelerate medical innovations into the clinic and ultimately to patients."

"We are extremely pleased to be working with Daiichi Sankyo," said Neil Fanger, Ph.D., President and Chief Executive Officer of Virtici. "Using our unique model, infrastructure and capabilities, we can help further advance Daiichi Sankyo's strong track record of innovative drug development. This collaboration leverages the complementary capabilities and synergies between our firms."

"This alliance represents a new partnership paradigm for Virtici and Celdara Medical while validating our underlying development model. Daiic
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... - The issue: In consultation ... lot (lot 710535) of Clavulin-400 (70mL) after receiving a complaint ... in one bottle of the  product. No other lots of ... Clavulin-400 is an oral antibiotic used in adults and children ... Clavulin-400 comes as a powder in bottles and is mixed ...
(Date:4/17/2015)... , April 17, 2015 Contego ... Integrated Embolic Protection™ filter platform for angioplasty balloon ... a $5.6 million Series B financing round led ... firm with a focus on medical devices, biopharmaceuticals, ... round also included Mountain Group Partners, Lookout Capital ...
(Date:4/17/2015)... April 17, 2015  Regulatory leaders in the pharmaceutical ... discussion draft called "21 st Century Cures." ... be taken up by Congress soon and if enacted ... device products are developed and marketed in ... companies have begun to consider how the proposed changes ...
Breaking Medicine Technology:Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle 2Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 321st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2
... 17, 2011 Xanodyne Pharmaceuticals, Inc., is pleased to ... position of Chief Operating Officer reporting to Natasha Giordano, ... has more than 20 years of experience in the ... senior positions in UCB Pharmaceuticals (Belgium, US and Japan). ...
... Cynosure, Inc. (Nasdaq: CYNO ), a ... invasive and non-invasive aesthetic applications, today announced the ... Company,s new flagship workstations for cellulite reduction. ... Australia,s Therapeutic Goods Administration (TGA) for its Cellulaze™ ...
Cached Medicine Technology:Xanodyne Pharmaceuticals Appoints New Chief Operating Officer 2Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations 2Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations 3
(Date:4/19/2015)... York, New York (PRWEB) April 19, 2015 ... Panel on Multidistrict Litigation (JPML) indicate that Lipitor lawsuits ... litigation underway in U.S. District Court, District of South ... 2,185 new cases have been filed in the proceeding ... diabetes due to their use of the cholesterol-lowering statin. ...
(Date:4/19/2015)... 19, 2015 Family and friends of Brad ... in Memory of Brad Baddeley event to honor his ... , Bowling for Brains is cheduled to take place on ... Street in Lincoln, Nebraska. Participants may arrive at 12:30pm on ... , The cost is only $4 per game and 100% ...
(Date:4/18/2015)... 2015 Carinsurancequotesinfo.com has released a new ... physical injuries caused by a car accident. ... for a vehicle. A policy can pay for car ... Drivers should always carry appropriate coverage when they are ... be bought with several important riders that offer extra ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Review of ... hosting a ‘Strategies for Success’ program for cataract surgeons ... meeting in San Diego, where eye surgeon Jeffrey L. ... this invitation-only event. Dr. Martin is the Managing Partner ... of Ophthalmology chose Dr. Martin to lead this year’s ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... chiefs have said “negative” to allegations that a perceived problem ... will upset the immunization// schedule of thousands of babies and ... of the Health IT initiative by the Government, to track ... problem, it is estimated that nearly 3,000 children would find ...
... to be believed neural transplants could be used to ... for a number of people came from a group ... provide improvement and a period of stability in Huntington's ... bad thing to happen to anyone. It is a ...
... scientists are of the opinion that women are in a ... that was conducted using rodents they found that female rodents ... shed light on health differences between males and females. ... 120 rats and measured in them what is known as ...
... to disclose the results of study findings with participants ... published in the April 1, 2006 issue of CANCER,// ... that such disclosures may actually do more harm than ... ,Maurie Markman, M.D., of the University of ...
... Claudia Twiby, eighteen months old was kept alive with a Berlin ... ,Four weeks later she received a new donated heart ... Lansdale, 32, and Shaun Twiby, 42. ,Claudia was only ... at London's Great Ormond Street Hospital, which first carried out the ...
... European regulators have not given the green signal to a ... . This is a step retrograde to a budding industry ... animals , ,GTC Biotherapeutics, proponents of this drug, ... the verdict came about only on the basis of a ...
Cached Medicine News:Health News:Men Are Less Capable Of Handling Stress Than Women – New Stud 2Health News:Regulators Object Drug Produced from Genetically Engineered Farm Animals 2
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... Vein Mapping. The LASSO Circular Mapping Catheter ... catheter capable of circumferentially mapping the myocardial ... unique design allows the sequential assessment of ... pulmonary vein isolation. The circular LASSO ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
Fixed and steerable lumen diagnostic mapping catheters are offered in a variety of catheter configurations...
Medicine Products: